SGLT2 inhibitor dapagliflozin

Overview

dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used as a therapeutic agent, most prominently in type 2 diabetes. By inhibiting SGLT2-mediated glucose reabsorption in the kidney, it promotes urinary glucose excretion and lowers blood glucose. Beyond glycemic control, dapagliflozin has been investigated for broader cardiometabolic and organ-protective effects, including potential benefits in the kidney, heart, and other tissues.

In recent biomedical research, dapagliflozin has been studied not only as a glucose-lowering therapy but also as a modulator of disease-associated pathways such as oxidative stress, ferroptosis, TGF-β signaling, and inflammatory injury. These studies place dapagliflozin within the broader class of sodium glucose cotransporter-2 (SGLT2) inhibitors, alongside agents such as empagliflozin, and suggest that its effects may extend into renal protection, cardiovascular remodeling, metabolic regulation, and possibly neurobiological outcomes.

Recent Publications Summary

Recent publications on dapagliflozin span analytical, clinical, translational, and preclinical research. One study developed a first-derivative synchronous spectrofluorimetric method for simultaneous quantification of dapagliflozin and sitagliptin in dosage forms and spiked human plasma, reporting good linearity, low limits of detection, and satisfactory accuracy and precision for both drugs 42471380Jul. In clinical and health-economic research, dapagliflozin was evaluated in adults with cardiovascular-kidney-metabolic syndrome in Spain using a cost-offset model over 3 years 42343656Jun, and in inactive lupus nephritis patients with residual proteinuria in a randomized crossover trial assessing efficacy and safety 41324239Dec. A protocol from Norway also described the DEAK study, which will prospectively assess dapagliflozin in de novo kidney transplant recipients to examine kidney function, histopathology, metabolic outcomes, and safety 42315275Jun.

Comparative effectiveness studies continued to position dapagliflozin within the broader SGLT2 inhibitor class. In a nationwide propensity-matched Korean study of adults with type 2 diabetes, empagliflozin and dapagliflozin showed broadly similar outcomes, while empagliflozin was associated with lower risks of hypoglycemia and all-cause hospitalization versus dapagliflozin 42342812Jun. Another real-world prospective cohort study in heart failure with reduced ejection fraction compared dapagliflozin with empagliflozin for major adverse cardiovascular events, reflecting ongoing interest in head-to-head assessment of these guideline-recommended therapies 42357835Jun. dapagliflozin was also used as the comparator in a phase 3 trial of orforglipron in adults with type 2 diabetes inadequately controlled on metformin, with dapagliflozin 10 mg serving as the active reference arm 42259339Jun. Additional hospitalized-care research examined dapagliflozin as add-on therapy to continuous subcutaneous insulin infusion in type 2 diabetes, focusing on efficacy and hypoglycemia-related safety 41916043Mar.

Mechanistic and disease-model studies suggest dapagliflozin may exert effects beyond glucose lowering. In diabetic nephropathy models, dapagliflozin attenuated ferroptosis and renal injury through activation of the Nrf2/HO-1 pathway, with increased SLC7A11, GPX4, and FTH1 and decreased TFRC1 reported in mice and high-glucose-cultured renal tubular cells 42099241May. In a rat model of diabetic cardiomyopathy, dapagliflozin was studied alongside suberoylanilide hydroxamic acid, with both agents reported to reduce oxidative stress markers and improve cardiac-related measures, including Cx43 expression 42156803May. dapagliflozin also attenuated focal cerebral ischemia-reperfusion injury in rats 42334656Jun, reduced HIV-associated cardiac fibrosis, steatosis, and diastolic dysfunction in mice via inhibition of TGFβ signaling 42054528Apr, and improved cognitive dysfunction-related endpoints in in silico and in vivo work in diabetic rats 41819428Mar. Additional preclinical work found that dapagliflozin altered plasma N-glycan profiles in obese mice in a time-of-day-dependent manner, with nighttime dosing normalizing several high-fat-diet-induced glycan changes despite limited effects on blood glucose or body weight 41948954Apr.

What Changes, What Holds

1. Analytical and early clinical work mainly extends dapagliflozin’s practical use rather than its biology
METHOD The new spectrofluorimetric assay adds a validated way to measure dapagliflozin, including in combination with sitagliptin and in plasma, so it changes how the drug can be quantified rather than what is known about its effects 42471380Jul. The clinical protocol and health-economic analysis likewise broaden the settings in which dapagliflozin is being assessed, but they do not yet alter the baseline account of its therapeutic role 42315275Jun42343656Jun.

2. Head-to-head and comparator studies sharpen dapagliflozin’s place within the SGLT2 class without overturning it
REINFORCES Comparative work continues to support dapagliflozin as a guideline-relevant SGLT2 inhibitor, while also suggesting that some outcomes may favor empagliflozin in certain real-world settings 42342812Jun42357835Jun. Using dapagliflozin as an active reference in a phase 3 diabetes trial and as add-on therapy to insulin infusion mainly reinforces its role as a standard comparator and adjunct, not a new use or mechanism 42259339Jun41916043Mar.

3. dapagliflozin’s proposed actions now extend into additional disease models and organ systems beyond the baseline account
NEW DIRECTION The new preclinical studies broaden the drug’s profile beyond glycemic control, renal protection, cardiovascular remodeling, and inflammatory injury by implicating it in ischemic brain injury, HIV-associated cardiac fibrosis, and cognition-related endpoints 42334656Jun42054528Apr41819428Mar. That does not contradict the Overview, but it does add organ- and disease-specific roles the baseline did not cover, while the ferroptosis and oxidative-stress findings further support the idea that its effects are mechanistically pleiotropic 42099241May42156803May.

Overview update candidates: preclinical evidence for effects in focal cerebral ischemia-reperfusion injury; HIV-associated cardiac fibrosis/diastolic dysfunction; and cognitive dysfunction-related endpoints; mechanistic evidence linking dapagliflozin to ferroptosis suppression via Nrf2/HO-1 signaling.